MedPath

QbTest Utility for Optimising Treatment in ADHD (QUOTA)

Not Applicable
Completed
Conditions
ADHD
Interventions
Device: QbTest
Registration Number
NCT03368573
Lead Sponsor
Nottinghamshire Healthcare NHS Trust
Brief Summary

Attention Deficit/Hyperactivity Disorder (ADHD) is a condition that affects 3-5% of young people under 18-years-old.

Young people with ADHD have difficulties with attention, impulsivity and hyperactivity that make it harder for them to learn, form relationships and prepare for adulthood. Clinical guidelines state that young people taking medication for ADHD should be closely monitored and have their medication reviewed regularly to ensure they receive the correct dose to improve their symptoms. However, many young people aren't monitored as closely as guidelines recommend. This can lead to lack of improvement or worsening of symptoms meaning that children may not experience the benefits of medication as quickly as they should. At the moment, assessing whether or not medication is working relies on the opinions of teachers and parents, collected through questionnaires. The difficulties of this are: differences of opinion between people, lack of information provided by them, and not returning the questionnaires. A test performed on a computer (QbTest) provides doctors with a report of the young person's symptoms and can therefore show whether medication is working. This may help doctors reach accurate decisions about medication dose more quickly, reducing the need for questionnaires. The study team met with families and young people with ADHD and medical experts and developed a procedure for using QbTest to measure medication effects. The study team will measure how well this procedure works in the real world by asking a group of young people to complete the test when they first start taking medication and at their follow-up appointments. The study team will ask doctors and families/young people for their opinions on the procedure.

The study team shall share our findings with other researchers and with the public by attending local support groups and providing summaries of the study results. The findings will be used to prepare for a future study.

Detailed Description

The primary objective of the study is to assess the feasibility and acceptability of the study design using a feasibility RCT.

The end-points to assess this objective are:

* Acceptability of randomisation. The number of patients who do not participate and state randomisation as the reason for non-participation. The study team shall also monitor drop-out rates immediately after randomisation and the number of errors in randomisation at each site.

* Acceptability of study design. The number of eligible patients at each site and the numbers who consent to take part/withdraw. Withdrawal rates will be recorded alongside time point in the trial to ascertain acceptability of the study duration.

* Acceptability of outcome measures. Completion rates for outcomes to determine most appropriate methods of data collection.

* Acceptability/feasibility of protocol. Record non-adherence of healthcare professionals to the protocol and explore reasons.

* Feasibility of future RCT. Estimate the hours per week needed to run the RCT and therefore the number of research assistants/fellows required and time commitment required by HCPs.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
43
Inclusion Criteria
  • Male or Female, aged 6-17 years (at the time of consent).
  • Participant is willing and able to give informed consent for participation in the study (if over 16-years).
  • Parental consent for children and young people aged under 16-years-old.
  • Referred to CAMHS or Community Pediatric services and diagnosed with ADHD.
  • Clinician and family (parent/carer and young person/child) agreement to commence stimulant medication for ADHD symptoms.
Exclusion Criteria
  • Unable to give informed consent
  • Severe learning difficulty
  • Not started on stimulant medication (either not started on medication at all or started on a non-stimulant medication)
  • Non-fluent English

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Experimental ArmQbTestParticipants in the experimental arm (QbTest) protocol will also undergo standard assessment as usual plus a QbTest. If a QbTest was not conducted within 12 weeks prior to starting medication (as part of the ADHD diagnostic assessment procedure) the young person will sit a QbTest at baseline (off medication). Once on medication they will sit another QbTest 2-4 weeks after commencing medication and again 8-10 weeks later (and no later than 12 weeks).
Primary Outcome Measures
NameTimeMethod
SNAP-IVFollow up 2 (8-10 weeks)

SNAP-IV is a short questionnaire designed to assess ADHD symptoms, with established validity, reliability and use in clinical and research settings. Completed by Parents and Teachers.

Secondary Outcome Measures
NameTimeMethod
CGI (Clinical Global Impressions Scale)Baseline (0 weeks), Follow up 2 (8-10 weeks)

Clinicians will be asked to complete the CGI. The CGI takes no longer than 5 minutes to complete and measures symptom severity and improvement due to medication.

Health Economic OutcomeFollow up 2 (8-10 weeks)

Measure of use of Health Services

Medication adherenceFollow up 1 (2-4 weeks) and Follow up 2 (8-10 weeks)

To look adherence to medication

Side Effects QuestionnaireFollow up 1 (2-4 weeks) and Follow up 2 (8-10 weeks)

To measure medication side effects

Qualitative InterviewsFollow up 2 (8-10 weeks)

To look at the acceptability of the intervention

SDQBaseline (0 weeks), Follow up 2 (8-10 weeks)

The SDQ is a short, well validated and well used clinical and research measure that assesses a range of behavioural and emotional issues in children and young people. Completed by parents and teachers.

CHU9DBaseline (0 weeks), Follow up 1 (2-4 weeks), Follow up 2 (8-10 weeks)

a short (5 minute) measure of quality of life. The CHU9D has been designed for use with children and young people and is very easy to complete

Trial Locations

Locations (1)

Nottinghamshire Healthcare NHS Foundation Trust

🇬🇧

Nottingham, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath